Totally 204 DN patients were recruited, and further assigned to 3 groups, i.e., the early DN group, the clinical stage of DN with normal renal function group, the clinical stage of DN with insufficient renal function group. Patients in the same group were randomly allocated to the
telmisartan treatment group, the SG treatment group, and the combination of SG and
telmisartan treatment group, 68 in each group. Patients in the
telmisartan treatment group took
telmisartan tablet, 80 mg per day, once daily. Those in the SG treatment group took SG, 5 g each time, 3 times per day. Those in the combination of SG and
telmisartan treatment group took
telmisartan tablet (80 mg per day, once daily) and SG (5 g each time, 3 times per day). The therapeutic course for all was 3 successive months. SCr levels, serum
urea nitrogen (BUN),24 h urine microalbumin (24 h U-MA) were detected before and
after treatment. Results In three different treatment groups, 24 h U-MA decreased
after treatment in the
telmisartan treatment group; SCr and BUN decreased
after treatment in the SG treatment group; and 24 h U-MA, SCr and BUN decreased
after treatment in the combination of SG and
telmisartan treatment group (P<0.05). In the clinical stage of DN with insufficient renal function group, SCr obviously increased
after treatment in the
telmisartan treatment group (P <0. 05). In the 3 DN stages, SCr and 24 h U-MA obviously decreased in the combination of SG and
telmisartan treatment group, when compared with the
telmisartan treatment group and the SG treatment group (P<0.05). Compared with the
telmisartan treatment group, SCr and BUN obviously decreased in the SG treatment group, but 24 h U-MA quantitation obviously increased (P<0.05). BUN obviously decreased in the combination of SG and
telmisartan treatment group (P<0. 05).
CONCLUSION: